Pande Atul 4

What Happened
Atul Pande, a director of Immunovant, exercised stock options to acquire 6,000 common shares at $8.43 per share (cost $50,580) on May 20, 2026, and sold 6,000 shares in an open‑market transaction the same day at $32.00 per share (proceeds $192,000). The filings also show a related derivative conversion/settlement entry for 6,000 shares at $0.00. Net proceeds from the exercise/sale sequence were approximately $141,420 before taxes and fees. The sale was executed pursuant to a prearranged Rule 10b5‑1 trading plan.

Key Details

• Transaction date: 2026-05-20
• Exercise: 6,000 shares at $8.43 — total cash paid $50,580 (transaction code M)
• Sale: 6,000 shares at $32.00 — total proceeds $192,000 (transaction code S)
• Derivative conversion/settlement: 6,000 shares at $0.00 noted (transaction code M)
• Footnotes: F1 — executed under a Rule 10b5‑1 plan adopted 2025‑12‑26; F2 — reflects a fully vested stock option award.
• Shares owned after the transactions: not specified in the filing.
• Filing timeliness: transaction date and report date are both 2026‑05‑20; the filing does not indicate a late report.

Context
This sequence shows an option exercise immediately followed by an open‑market sale (a common pattern when insiders exercise vested options and sell shares to cover cost/taxes or realize gains). The presence of a 10b5‑1 plan means the trades were preplanned and executed according to that plan’s instructions. These actions are routine insider liquidity events and do not, by themselves, indicate new company guidance or insider sentiment beyond the sale of the exercised shares.